Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Argenx Se ADR (NQ: ARGX ) 565.00 +21.16 (+3.89%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 375,122 Open 545.99 Bid (Size) 559.00 (1) Ask (Size) 845.70 (2) Prev. Close 543.84 Today's Range 542.80 - 565.11 52wk Range 327.73 - 565.11 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Latest Analyst Ratings For argenx October 17, 2024 Via Benzinga argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions October 15, 2024 From argenx SE Via GlobeNewswire Performance YTD +48.29% +48.29% 1 Month +6.79% +6.79% 3 Month +19.88% +19.88% 6 Month +56.84% +56.84% 1 Year +17.75% +17.75% More News Read More Biotech Stocks : Are You A Trader Or A Longer Term Investor? October 01, 2024 Via Talk Markets Peeling Back The Layers: Exploring argenx Through Analyst Insights September 26, 2024 Via Benzinga Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases September 25, 2024 Via Investor's Business Daily What 25 Analyst Ratings Have To Say About argenx August 23, 2024 Via Benzinga The Analyst Verdict: argenx In The Eyes Of 27 Experts July 29, 2024 Via Benzinga Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session September 24, 2024 Via Benzinga argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy September 19, 2024 From argenx SE Via GlobeNewswire Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB August 29, 2024 Via Benzinga Exposures Product Safety argenx to Present at Upcoming Investor Conferences August 28, 2024 From argenx SE Via GlobeNewswire 10 Health Care Stocks With Whale Alerts In Today's Session August 12, 2024 Via Benzinga This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday August 06, 2024 Via Benzinga Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday July 29, 2024 Via Benzinga argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update July 25, 2024 From argenx SE Via GlobeNewswire argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024 July 18, 2024 From argenx SE Via GlobeNewswire argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China July 16, 2024 From argenx SE Via GlobeNewswire Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China July 16, 2024 From Zai Lab Limited Via Business Wire argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting June 25, 2024 From argenx SE Via GlobeNewswire Why Is European Drugmaker Argenx Stock Trading Higher On Monday? June 24, 2024 Via Benzinga Exposures Product Safety Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval June 24, 2024 Via Investor's Business Daily Exposures Product Safety Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday June 24, 2024 Via Benzinga RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session June 24, 2024 Via Benzinga argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy June 21, 2024 From argenx SE Via GlobeNewswire argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024 June 17, 2024 From argenx SE Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.